window.pageData = {"stock":{"_id":3000000024379,"stockCode":"024379","masterFundShortName":"平安港股通医疗创新精选混合","fundSecondLevel":"hybrid","stockType":"fund","areaCode":"cn","market":"a","tickerId":24379,"currency":"CNY","masterFundFlag":1,"status":"normal","exchange":"jj","shortName":"平安港股通医疗创新精选混合A","name":"平安港股通医疗创新精选混合型证券投资基金","pinyin":"paggtylcxjxhhxzqtzjj","fundCollectionId":4000050640000,"setUpAssetScale":89138856.59,"setUpDate":"2025-06-10T16:00:00.000Z","setUpShares":89138856.59,"inceptionDate":"2025-06-12T16:00:00.000Z","followedNum":7,"fundCollection":{"exchange":"jjgs","stockType":"fund_collection","stockCode":"50640000","tickerId":50640000,"name":"平安基金管理有限公司"},"managers":[{"name":"周思聪","stockType":"fund_manager","stockCode":"8801381514","exchange":"fm","tickerId":261903140470},{"name":"张淼","stockType":"fund_manager","stockCode":"8801394991","exchange":"fm","tickerId":2613150030}],"hotMetrics":{"fss":{"stockId":3000000024379,"type":"fss","last_data_date":"2025-12-30T16:00:00.000Z","f_ins_h_s_r":0.2884,"f_ind_h_s_r":0.7116,"f_h_a":2621},"fpr":{"stockId":3000000024379,"type":"fpr","f_cagr_p_r_fs_ssc":9328,"f_cagr_p_r_fs_ssrp":0.9577570494263965,"f_p_r_m1_ssc":9334,"f_p_r_m1_ssrp":0.07168113146898103,"f_p_r_m3_ssc":9171,"f_p_r_m3_ssrp":0.9696837513631407,"f_p_r_m6_ssc":8947,"f_p_r_m6_ssrp":0.8191370444891571,"f_p_r_fys_ssc":8947,"f_p_r_fys_ssrp":0.8195841716968477,"f_p_r_y1_ssc":8422,"f_p_r_y1_ssrp":0.9539247120294502},"fp":{"stockId":3000000024379,"type":"fp","last_data_date":"2026-07-02T16:00:00.000Z","f_cagr_p_r_fs":-0.08808060879753687,"f_p_r_m1":0.1393525543753158,"f_p_r_m3":-0.12769871236324937,"f_p_r_m6":-0.046661728917575584,"f_p_r_fys":-0.046661728917575584,"f_i_d":"2025-06-12T16:00:00.000Z","f_p_r_y1":-0.09719438877755682},"ff":{"stockId":3000000024379,"type":"ff","f_fr_d":"2025-12-30T16:00:00.000Z","f_m_fr":0.012,"f_c_fr":0.002,"f_mac_fr":0.014},"f_nlacan":{"stockId":3000000024379,"type":"f_nlacan","f_nv_d":"2026-07-02T16:00:00.000Z","f_nv":0.901,"f_nv_cr":0.046336081755893765},"f_as":{"stockId":3000000024379,"type":"f_as","f_tas":144184676.868,"f_tas_d":"2026-03-30T16:00:00.000Z"}},"masterSlaveFunds":[{"_id":3000000024380,"name":"平安港股通医疗创新精选混合型证券投资基金","fundSecondLevel":"hybrid","stockType":"fund","areaCode":"cn","market":"a","status":"normal","stockCode":"024380","tickerId":24380,"shortName":"平安港股通医疗创新精选混合C","currency":"CNY","__csrcFundId":15184,"exchange":"jj","masterFundFlag":null,"indexFundFlag":null,"activeFundFlag":null,"etfFundFlag":null,"lofFundFlag":null,"pensionTargetFlag":null,"feederFundFlag":null,"classificationFlag":null,"closedEnd":null,"lastUpdated":"2025-06-23T08:42:13.119Z","inceptionDate":"2025-06-12T16:00:00.000Z","pinyin":"paggtylcxjxhhxzqtzjj","fundCollectionId":4000050640000}],"shareholdings":[{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000024379,"stockId":1000000000002268,"holdings":569000,"marketCap":29239595,"netValueRatio":0.1037,"quarterlyChange":-0.04197530864197552,"stock":{"stockCode":"02268","exchange":"hk","stockType":"company","tickerId":2268,"name":"药明合联"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000024379,"stockId":1000000000009926,"holdings":253000,"marketCap":29084902,"netValueRatio":0.1031,"quarterlyChange":0.1522123893805305,"stock":{"stockType":"company","exchange":"hk","stockCode":"09926","tickerId":9926,"name":"康方生物"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000024379,"stockId":1000000000006990,"holdings":70300,"marketCap":28552837,"netValueRatio":0.1012,"quarterlyChange":0.17287098419173907,"stock":{"exchange":"hk","stockType":"company","stockCode":"06990","tickerId":6990,"name":"科伦博泰生物"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000024379,"stockId":1000000000001801,"holdings":367500,"marketCap":27548702,"netValueRatio":0.0977,"quarterlyChange":0.11344262295081897,"stock":{"stockCode":"01801","exchange":"hk","stockType":"company","tickerId":1801,"name":"信达生物"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000024379,"stockId":1000000000009995,"holdings":298500,"marketCap":25249103,"netValueRatio":0.0895,"quarterlyChange":0.33055555555555527,"stock":{"stockType":"company","exchange":"hk","stockCode":"09995","tickerId":9995,"name":"荣昌生物"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000024379,"stockId":1000000000006160,"holdings":164900,"marketCap":24984694,"netValueRatio":0.0886,"quarterlyChange":-0.04294478527607337,"stock":{"stockCode":"06160","exchange":"hk","stockType":"company","tickerId":6160,"name":"百济神州"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000024379,"stockId":1000000000001530,"holdings":1224000,"marketCap":24467745,"netValueRatio":0.0868,"quarterlyChange":-0.06368899917286963,"stock":{"stockCode":"01530","exchange":"hk","stockType":"company","tickerId":1530,"name":"三生制药"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000024379,"stockId":1000000000002315,"holdings":362000,"marketCap":17691404,"netValueRatio":0.0627,"quarterlyChange":0.5679886685552415,"stock":{"exchange":"hk","stockType":"company","stockCode":"02315","tickerId":2315,"name":"百奥赛图-B"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000024379,"stockId":1000000000009606,"holdings":60200,"marketCap":15680309,"netValueRatio":0.0556,"quarterlyChange":-0.010731052984573997,"stock":{"exchange":"hk","stockType":"company","stockCode":"09606","tickerId":9606,"name":"映恩生物-B"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000024379,"stockId":1000000000003347,"holdings":424100,"marketCap":15517584,"netValueRatio":0.055,"quarterlyChange":-0.025660279823018994,"stock":{"stockType":"company","exchange":"hk","stockCode":"03347","tickerId":3347,"name":"泰格医药"}}],"bondHoldings":[{"_id":"69e8fbea1398d798430040ba","date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000024379,"stockCode":"019773","stockName":"25国债08","holdings":76000,"marketCap":7700886,"netValueRatio":0.0273,"lastUpdated":"2026-04-22T16:48:42.768Z"}],"lastFsMetrics":{"latestTurnoverRate":1.108578023479077,"latestTurnoverRateDate":"2025-12-30T16:00:00.000Z"}},"list":[{"_id":"69e8ec9c1398d79843fe9ff2","date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","stockId":3000000024379,"sao":"2026年一季度国内经济相对平稳，消费温和修复，地产仍处调整阶段，新质生产力相关产业表现相对亮眼。海外方面，美国经济韧性较强、通胀黏性犹存，美联储降息节奏延后，高利率环境持续；欧元区与日本复苏偏弱，全球经济分化格局延续。流动性上，国内货币政策维持偏松基调，财政靠前发力，市场流动性合理充裕；海外美元偏强，新兴市场资金面承压。地缘政治风险显著抬升，中东局势紧张加剧能源价格波动，俄乌冲突及区域摩擦持续推升全球风险溢价。A股市场整体呈结构性震荡，成交维持高位，市场波动加大，主线清晰但轮动较快。　　医药行业方面，政策端迎来战略定位跃升，2026年政府工作报告将生物医药列为新兴支柱产业。这是政府工作报告中首次以支柱产业的定位提出发展生物医药产业，释放出推动产业加速升级的重要政策信号，医药产业的国家战略地位正在进一步提升。将生物医药明确定位为“新兴支柱产业”，意味着国家层面对该产业的战略重视程度进一步提升，也有望在政策、资本以及产业生态等多个层面形成更强的支持合力。出海方面，创新药出海爆发式增长，一季度对外授权交易总额超600亿美元，接近2025年全年一半，首付款超33亿美元，平均单笔首付1.84亿美元，创历史新高。业绩方面，随着2025年年报的发布，多家上市公司宣布盈利，上市公司业绩持续修复，行业盈利拐点确立。　　本报告期内，以子行业的景气度为投资的重要策略，在商业模式、竞争力和业绩的多维度比较中寻找具有估值性价比的优秀公司，重点布局了创新药方向。未来仍然看好以创新药、创新医疗器械、医药外包服务为代表的成长型的医药子行业。","lastUpdated":"2026-04-22T15:43:24.846Z","fund":{"_id":3000000024379,"__csrcFundId":15184,"stockCode":"024379","masterFundShortName":"平安港股通医疗创新精选混合","fundSecondLevel":"hybrid","stockType":"fund","areaCode":"cn","market":"a","tickerId":24379,"currency":"CNY","masterFundFlag":1,"status":"normal","exchange":"jj","shortName":"平安港股通医疗创新精选混合(024379)","lastUpdated":"2026-05-01T04:14:19.651Z","name":"平安港股通医疗创新精选混合型证券投资基金","pinyin":"paggtylcxjxhhxzqtzjj","fundCollectionId":4000050640000,"setUpAssetScale":89138856.59,"setUpDate":"2025-06-10T16:00:00.000Z","setUpShares":89138856.59,"inceptionDate":"2025-06-12T16:00:00.000Z","followedNum":7,"managers":[{"stockCode":"8801381514","stockType":"fund_manager","exchange":"fm","tickerId":261903140470,"name":"周思聪"},{"stockCode":"8801394991","stockType":"fund_manager","exchange":"fm","tickerId":2613150030,"name":"张淼"}]},"announcement":{"linkText":"平安港股通医疗创新精选混合型证券投资基金 2026年第1季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1479163","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69cd159a5c96f51c69ab8af4","date":"2025-12-30T16:00:00.000Z","declarationDate":"2026-03-30T16:00:00.000Z","stockId":3000000024379,"sao":"2025年是全球经济在多重结构性压力与政策调整中寻求再平衡的关键一年。面对地缘政治持续紧张、主要经济体货币政策路径分化、技术变革加速以及气候转型压力加剧等多重挑战，全球经济增长呈现出“整体放缓、结构分化”的显著特征。国际货币基金组织（IMF）预测，2025年全球GDP增速将处于2.8%至3.2%区间，较疫情前长期趋势水平有所回落，反映出全球经济动能减弱的现实。中国在2025年实现了约5%的GDP增长，显著高于全球平均水平，在全球主要经济体中继续保持前列。政府出台一系列稳增长政策的持续发力，包括财政政策适度扩张、货币政策精准滴灌、房地产风险有序化解以及科技创新投入加大。流动性方面，2025年全球流动性环境经历了从“紧缩尾声”向“宽松预期”的过渡。上半年，美联储、欧洲央行等主要央行仍维持高利率政策，全球美元流动性持续偏紧，美元指数一度走强，对新兴市场形成压力。但随着美国通胀数据逐步回落、经济增长放缓，市场对降息的预期不断增强，10年期美债收益率回落，全球金融条件有所放松。中国在2025年实施了积极的流动性管理政策，有效提升了A股市场的流动性供给，成为支撑市场活跃的重要因素。2025年A股市场表现亮眼，成为全球最具活力的资本市场之一，港股市场整体呈现震荡修复态势，表现弱于A股。　　医药政策方面，医药行业利好政策频繁出台，产业指向性明确，创新药国内审批显著提速。国务院办公厅发布《关于全面深化药品医疗器械监管改革促进医药产业高质量发展的意见》，明确表示加大对药品医疗器械研发创新的支持力度，全力支持重大创新；提高药品医疗器械审评审批质效，加速获批上市时间。三季度，卫健委、医保局联合发布《支持创新药高质量发展的若干措施》，提出了多项支持创新药发展的政策，本次会议具有划时代的意义，首次出台商保目录，体现了1+3+N的多层次医疗保障体系，体现了医保局对于差异化、优质创新药的支持，在政策的鼓励和支持下，未来创新药在医保和商保端的放量值得期待。各类文件全文通读下来发现对创新药的鼓励支持力度非常大，且不同于前几次这次非常实际具体，在商保、入院、定价方面都给出了非常好的鼓励政策，行业政策超出预期。四季度的医保谈判，2025年创新药医保谈判的成功率创下历史新高，各种数据公布和对外授权均符合预期。医药行业基本面方面，创新药出海延续了前几年高歌猛进的势头，全年对外授权的数量、金额远超去年全年，出海总金额超过1300亿美元，并且在全球的占比均较去年同期继续走高，多单市场高度关注的创新药对外授权落地，首付款及总金额均大超市场预期。2025年对外授权（BD）活动的规模达到了前所未有的水平，2025年交易金额呈爆炸式增长。同时，优质临床数据的不断读出，也促成了持续的数据催化和BD交易催化。数据披露方面，今年学术大会上全球最亮眼的数据70%左右都来自中国企业的贡献，中国创新药药企集体闪耀全球。业绩方面，随着大量创新药纳入医保，国产创新药进入业绩释放周期，今年的中报，三分之一的创新药个股实现了收入50%以上的增长，创新药企业逐季度兑现的报表，将逐步夯实创新药个股的价值基础。尽管医药行业也受到来自关税、特朗普希望降低药价等多次扰动，但是创新药行业上半年持续上涨，尽管四季度出现一定的回落，但是全年依然有较好的涨幅。　　本报告期内，以子行业的景气度为投资的重要策略，在商业模式、竞争力和业绩的多维度比较中寻找具有估值性价比的优秀公司，重点布局了创新药方向。未来仍然看好以创新药、创新医疗器械、医药外包服务为代表的成长型的医药子行业。","lastUpdated":"2026-04-01T12:54:50.873Z","mo":"2025年被视为中国Biotech的“全球化元年”，数据极其震撼，交易数量和金额，远超2024年全年水平，也引发了市场对于创新药资产的重估行情。这一现象的背后隐含了三个深层次的产业逻辑变化：1、资产质量的全球认可：跨国药企不再仅仅将中国视为销售市场，而是将其视为核心研发管线的补充来源。2、现金流模式的重构：巨额的首付款直接改善了Biotech公司的资产负债表，使其在资本寒冬中无需依赖股权融资即可维持高强度的研发投入，创新药企业的造血能力大幅度改善。3、中国创新药企业差异化竞争优势的确立：中国创新药企在特定技术领域已形成集团军优势，这标志着中国在双抗、ADC等前沿领域的研发已具备全球Best-in-Class（同类最佳）的实力。2025是资本市场对于创新药行业的重新认知的元年，市场热衷于对中小市值的创新药企业进行重估，2025年中国创新药板块的强劲反弹标志着中长期维度大行情周期的第一阶段——估值重估的开启。全球BD交易的爆炸式增长验证了国内研发的质量，并开启了一个全新的价值创造渠道。但是，这仅仅体现了中国创新药研发能力在全球舞台上得到验证而带来大量的BD这一个方面，基本没有演绎创新药行业的业绩主线，因此2025年如火如荼的创新药行业行情仅仅是由于BD交易而带来的创新药投资情绪的好转。　　展望2026年，市场的叙事将从广泛的估值重估转向进一步的基本面落地。未来的赢家将是那些能够成功地将其科学创新转化为国内外商业成功的公司。市场将更加严苛地审视公司的每一个临床数据、每一份销售财报和每一次BD交易的质量。能否持续产出有价值的创新成果，以及能否将这些成果高效地转化为商业收入，是决定未来公司价值的核心。对创新药板块进行广泛、简单投资的时期正在结束，集体重估之后，中国创新药行业正进入其成长故事中一个更成熟的新阶段。2026年，将是创新药公司分化的重要时期，必须严格区分可持续的、基本面驱动的增长的标的与短暂的市场炒作的标的。躺着买整个板块就能赚钱的时期已经过去，拥有全球竞争力的核心资产、有商业化能力和财务状况相对稳健的公司有望在未来拥有更好的前景。","fund":{"_id":3000000024379,"__csrcFundId":15184,"stockCode":"024379","masterFundShortName":"平安港股通医疗创新精选混合","fundSecondLevel":"hybrid","stockType":"fund","areaCode":"cn","market":"a","tickerId":24379,"currency":"CNY","masterFundFlag":1,"status":"normal","exchange":"jj","shortName":"平安港股通医疗创新精选混合(024379)","lastUpdated":"2026-05-01T04:14:19.651Z","name":"平安港股通医疗创新精选混合型证券投资基金","pinyin":"paggtylcxjxhhxzqtzjj","fundCollectionId":4000050640000,"setUpAssetScale":89138856.59,"setUpDate":"2025-06-10T16:00:00.000Z","setUpShares":89138856.59,"inceptionDate":"2025-06-12T16:00:00.000Z","followedNum":7,"managers":[{"stockCode":"8801381514","stockType":"fund_manager","exchange":"fm","tickerId":261903140470,"name":"周思聪"},{"stockCode":"8801394991","stockType":"fund_manager","exchange":"fm","tickerId":2613150030,"name":"张淼"}]},"announcement":{"linkText":"平安港股通医疗创新精选混合型证券投资基金 2025年年度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1457900","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aed3fd7fea5b3eb0543a04","date":"2025-09-29T16:00:00.000Z","declarationDate":"2025-10-27T16:00:00.000Z","stockId":3000000024379,"sao":"三季度，国内经济保持稳定增长，消费和政策支持是主要驱动力。国家发改委推出5000亿元的新型政策性金融工具，以应对有效需求不足。房地产投资持续探底，但政策在总量和结构上同步加力，新一轮布局已全面启动，以稳定房地产市场。总体来说，国内经济发展状况整体平稳。全球经济增长乏力，通胀压力犹存，制造业恢复平稳，但贸易环境仍不稳定。流动性方面，央行的降准降息措施释放了约1万亿元的长期流动性，为市场提供了充裕的资金环境，美联储的宽松货币政策也创造了较好的资金条件。资本市场在三季度呈现稳健修复态势，A股整体表现较好，主要指数波动幅度收窄，市场情绪逐步回暖，交易活跃度较二季度有所提升。同时，市场呈现结构性分化，科技行业、产业周期和内需自主可控相关板块受到重点关注，显示出较强的投资潜力。港股市场在三季度同样表现良好。　　医药方面，医药指数三季度跟随大盘上涨，创新药行业在三季度前期大幅度走强，三季度后期进入震荡行情。政策方面，卫健委、医保局联合发布《支持创新药高质量发展的若干措施》，提出了多项支持创新药发展的政策，本次会议具有划时代的意义，首次出台商保目录，体现了1+3+N的多层次医疗保障体系，体现了医保局对于差异化、优质创新药的支持，在政策的鼓励和支持下，未来创新药在医保和商保端的放量值得期待。业绩方面，伴随着大量创新药纳入医保，国产创新药进入业绩释放周期，今年的中报，三分之一的创新药个股实现了收入50%以上的增长，今年预计有三分之一创新药企业实现盈利，创新药企业逐季度兑现的报表，将逐步夯实创新药个股的价值基础。出海方面，对外授权（BD）活动的规模达到了前所未有的水平，2025年交易金额呈爆炸式增长，远超往年。同时，优质临床数据的不断读出，也促成了持续的数据催化和BD交易催化。　　本报告期内，以子行业的景气度为投资的重要策略，在商业模式、竞争力和业绩的多维度比较中寻找具有估值性价比的优秀公司，重点布局了创新药方向。未来仍然看好以创新药、创新医疗器械为代表的成长型的医药子行业。","lastUpdated":"2026-03-09T14:06:53.166Z","fund":{"_id":3000000024379,"__csrcFundId":15184,"stockCode":"024379","masterFundShortName":"平安港股通医疗创新精选混合","fundSecondLevel":"hybrid","stockType":"fund","areaCode":"cn","market":"a","tickerId":24379,"currency":"CNY","masterFundFlag":1,"status":"normal","exchange":"jj","shortName":"平安港股通医疗创新精选混合(024379)","lastUpdated":"2026-05-01T04:14:19.651Z","name":"平安港股通医疗创新精选混合型证券投资基金","pinyin":"paggtylcxjxhhxzqtzjj","fundCollectionId":4000050640000,"setUpAssetScale":89138856.59,"setUpDate":"2025-06-10T16:00:00.000Z","setUpShares":89138856.59,"inceptionDate":"2025-06-12T16:00:00.000Z","followedNum":7,"managers":[{"stockCode":"8801381514","stockType":"fund_manager","exchange":"fm","tickerId":261903140470,"name":"周思聪"},{"stockCode":"8801394991","stockType":"fund_manager","exchange":"fm","tickerId":2613150030,"name":"张淼"}]},"announcement":{"linkText":"平安港股通医疗创新精选混合型证券投资基金 2025年第3季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1378690","linkType":"PDF","source":"csrc_pdf"}}]}